文献速递骨质疏松与代谢性骨病

估计2型糖尿病药物对骨折风险安全性的真实世界证据生成方法范围综述

A scoping review of real-world evidence generation methods to estimate the safety of type 2 diabetes medications on fracture risk.
PubMed 文献 · Osteoporos Int · 2025-11-21

本范围综述检索MEDLINE、Embase和CINAHL数据库2000年1月至2022年12月发表的英文全文文献,纳入50项使用医疗行政数据定义暴露与结局、以2型糖尿病药物为主要暴露、骨折为主要结局的研究。研究发现真实世界证据方法存在较大差异,少数研究考虑生物学合理性或治疗转换,仅46%的研究定义了骨折的测量方式。

要点

  • 纳入50项研究,其中40项队列研究、9项病例对照研究、1项自身对照病例系列研究。
  • 60%的队列研究和所有病例对照研究采用意向性治疗法定义药物暴露。
  • 40%的研究报告了暴露-结局风险窗口,但仅2项队列研究说明了生物学合理性。

核心结论

  • 研究识别出用于调查2型糖尿病药物与骨折风险的真实世界证据方法存在较大差异。
  • 少数研究在设计时考虑了生物学合理性或治疗转换,或提供足够细节以便重复。
  • 研究结果强调需要方法学设计指导以研究慢性病的长期药物治疗,并需要文化转变以提高报告透明度。

研究设计与样本

  • 范围综述,检索MEDLINE(OVID)、Embase(OVID)和CINAHL(EBSCO)数据库2000年1月至2022年12月发表的英文全文文章,研究对象为成人。
  • 纳入标准为:(1)主要暴露为2型糖尿病药物;(2)主要结局为骨折;(3)暴露和结局使用医疗行政数据定义。
  • 共纳入50项符合条件的研究(40项队列研究、9项病例对照研究、1项自身对照病例系列研究)。

主要发现

  • 大多数队列研究(60%)和所有病例对照研究采用意向性治疗法定义药物暴露。
  • 1项队列研究考虑了时间趋势。
  • 40%的研究(19项队列研究和1项病例对照研究)报告了暴露-结局风险窗口,但仅2项队列研究说明了生物学合理性。
  • 仅46%的研究定义了骨折的测量方式。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies provide real-world evidence (RWE) about the long-term effectiveness and rare side effects of medications. However, conflicting results from RWE studies exist regarding the relationship between type 2 diabetes mellitus (T2DM) medications and fracture risk. The objective of this scoping review was to summarize RWE methods employed to estimate the effect of T2DM medication on fracture risk. METHODS: We searched MEDLINE (OVID), Embase (OVID), and CINAHL (EBSCO) databases for full-text articles published between January 2000 and December 2022 in English and conducted in adults. Studies were included if: (1) the primary exposure was T2DM medication(s), (2) the primary outcome was fracture, and (3) the exposure and outcome were defined using healthcare administrative data. Study design, exposure and outcome measures, and analytical approaches were abstracted and summarized. RESULTS: We identified 50 eligible studies (40 cohort, 9 case-control, 1 self-controlled case series). Most cohort (60%) and all case-control studies defined medication exposure using an intention-to-treat approach. One cohort study considered time trends; 40% of studies (19 cohort and 1 case-control) reported an exposure-outcome risk window, although few (2 cohort studies) justified biological plausibility, and only 46% of studies defined how fractures were measured. CONCLUSION: We identified large variation in RWE methods used to investigate T2DM medications and fracture risk. Few studies considered biological plausibility or transitions in therapy in their design or provided detail to be able to replicate. Our findings highlight the need for guidance in methodological design to study long-term pharmacotherapy for chronic conditions and a culture shift to improve transparent reporting.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Spagnuolo MC, Shogry FF, Park S, et al. A scoping review of real-world evidence generation methods to estimate the safety of type 2 diabetes medications on fracture risk. Osteoporos Int. 2025. PMID: 41269289. doi:10.1007/s00198-025-07745-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。